IL123642A - Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration - Google Patents
Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regenerationInfo
- Publication number
- IL123642A IL123642A IL12364296A IL12364296A IL123642A IL 123642 A IL123642 A IL 123642A IL 12364296 A IL12364296 A IL 12364296A IL 12364296 A IL12364296 A IL 12364296A IL 123642 A IL123642 A IL 123642A
- Authority
- IL
- Israel
- Prior art keywords
- mononuclear phagocytes
- axonal regeneration
- pharmaceutical compositions
- mammal
- methods
- Prior art date
Links
- 210000002864 mononuclear phagocyte Anatomy 0.000 title abstract 4
- 230000003376 axonal effect Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 230000000735 allogeneic effect Effects 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000001616 monocyte Anatomy 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004207 dermis Anatomy 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- External Artificial Organs (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Secondary Cells (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52884595A | 1995-09-15 | 1995-09-15 | |
| US08/695,351 US5800812A (en) | 1995-09-15 | 1996-08-09 | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| PCT/US1996/014578 WO1997009885A1 (en) | 1995-09-15 | 1996-09-12 | Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL123642A0 IL123642A0 (en) | 1998-10-30 |
| IL123642A true IL123642A (en) | 2005-08-31 |
Family
ID=27062850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12364296A IL123642A (en) | 1995-09-15 | 1996-09-12 | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5800812A (xx) |
| EP (1) | EP0952772B1 (xx) |
| JP (1) | JP4100707B2 (xx) |
| AT (1) | ATE290789T1 (xx) |
| AU (1) | AU714205B2 (xx) |
| CA (1) | CA2232262A1 (xx) |
| DE (1) | DE69634499T2 (xx) |
| DK (1) | DK0952772T3 (xx) |
| ES (1) | ES2241002T3 (xx) |
| IL (1) | IL123642A (xx) |
| NZ (1) | NZ319365A (xx) |
| PT (1) | PT952772E (xx) |
| WO (1) | WO1997009885A1 (xx) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| JP2001511456A (ja) | 1997-08-04 | 2001-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 神経学的欠損を治療する方法 |
| US20010007657A1 (en) * | 1997-08-04 | 2001-07-12 | Reid James Steven | Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |
| US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| WO1999060021A2 (en) * | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| SE9802264D0 (sv) | 1998-06-25 | 1998-06-25 | Neuronova Ab | A method of isolating cells |
| US6541247B1 (en) | 1998-06-25 | 2003-04-01 | Neuronova Ab | Method of isolating ependymal neural stem cells |
| IL125983A0 (en) * | 1998-08-30 | 1999-04-11 | Yeda Res & Dev | Pharmaceutical composition comprising factor xiiia |
| DE60231263D1 (de) * | 2001-03-12 | 2009-04-02 | Inst Of Gene And Brain Science | Granulocyte-macrophage colony-stimulating factor (GM-CSF) als Heilmittel für Nervenschäden |
| KR20100087781A (ko) * | 2001-11-21 | 2010-08-05 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 인간 단핵 식세포성 백혈구의 제조 방법 |
| WO2003105750A2 (en) * | 2002-06-14 | 2003-12-24 | Yeda Research And Development Co. Ltd | Antigen-presenting cells for neuroprotection and nerve regeneration |
| WO2006056998A2 (en) * | 2004-11-29 | 2006-06-01 | Yeda Research And Development Co. Ltd. | Methods of cell therapy, neurogenesis and oligodendrogenesis |
| WO2010031006A1 (en) * | 2008-09-12 | 2010-03-18 | Cryopraxis Criobiologia Ltda. | Ischemic tissue cell therapy |
| CN104159590A (zh) | 2011-12-14 | 2014-11-19 | 耶达研究与开发有限公司 | 用于治疗中枢神经系统损伤的人单核细胞亚群 |
| CN105377273A (zh) | 2013-05-22 | 2016-03-02 | 耶达研究与发展公司 | 用于治疗眼睛疾病或病症的人类单核细胞亚群 |
| WO2018200750A1 (en) * | 2017-04-25 | 2018-11-01 | Purdue Research Foundation | 3-dimensional (3d) tissue-engineered muscle for tissue restoration |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157024A (en) * | 1977-10-16 | 1992-10-20 | Strategic Medical Research Corporation | Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals |
| IL71440A0 (en) * | 1984-04-04 | 1984-07-31 | Univ Ramot | Composition for nerve regeneration |
| US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| IL97365A0 (en) * | 1991-02-27 | 1992-05-25 | Yeda Res & Dev | Pharmaceutical compositions comprising a lymphokine |
| IL91459A0 (en) * | 1989-08-28 | 1990-04-29 | Yeda Res & Dev | Oligodendrocyte inhibitory factor |
-
1996
- 1996-08-09 US US08/695,351 patent/US5800812A/en not_active Expired - Lifetime
- 1996-09-12 PT PT96932991T patent/PT952772E/pt unknown
- 1996-09-12 WO PCT/US1996/014578 patent/WO1997009885A1/en active IP Right Grant
- 1996-09-12 CA CA002232262A patent/CA2232262A1/en not_active Abandoned
- 1996-09-12 JP JP51207797A patent/JP4100707B2/ja not_active Expired - Fee Related
- 1996-09-12 AT AT96932991T patent/ATE290789T1/de not_active IP Right Cessation
- 1996-09-12 EP EP96932991A patent/EP0952772B1/en not_active Expired - Lifetime
- 1996-09-12 DE DE69634499T patent/DE69634499T2/de not_active Expired - Lifetime
- 1996-09-12 IL IL12364296A patent/IL123642A/xx not_active IP Right Cessation
- 1996-09-12 NZ NZ319365A patent/NZ319365A/xx not_active IP Right Cessation
- 1996-09-12 DK DK96932991T patent/DK0952772T3/da active
- 1996-09-12 AU AU71572/96A patent/AU714205B2/en not_active Ceased
- 1996-09-12 ES ES96932991T patent/ES2241002T3/es not_active Expired - Lifetime
-
1997
- 1997-03-14 US US08/818,818 patent/US6117424A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0952772B1 (en) | 2005-03-16 |
| US6117424A (en) | 2000-09-12 |
| US5800812A (en) | 1998-09-01 |
| IL123642A0 (en) | 1998-10-30 |
| DE69634499D1 (de) | 2005-04-21 |
| DE69634499T2 (de) | 2006-01-05 |
| JPH11513370A (ja) | 1999-11-16 |
| EP0952772A1 (en) | 1999-11-03 |
| WO1997009885A1 (en) | 1997-03-20 |
| DK0952772T3 (da) | 2005-07-18 |
| CA2232262A1 (en) | 1997-03-20 |
| ES2241002T3 (es) | 2005-10-16 |
| JP4100707B2 (ja) | 2008-06-11 |
| EP0952772A4 (en) | 2002-01-02 |
| AU714205B2 (en) | 1999-12-23 |
| PT952772E (pt) | 2005-07-29 |
| ATE290789T1 (de) | 2005-04-15 |
| NZ319365A (en) | 1999-08-30 |
| AU7157296A (en) | 1997-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
| ES2163034T3 (es) | Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. | |
| WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
| HUS1400034I1 (hu) | Dialkil-fumarátok alkalmazása autoimmun betegségek kezelésére szolgáló gyógyászati készítmények elõállítására | |
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| AR003989A1 (es) | Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica. | |
| PT1137436E (pt) | Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 | |
| AU2782499A (en) | Isolated stromal cells for use in the treatment of diseases of the central nervous system | |
| MY122383A (en) | Cyclic boroproline compounds | |
| WO1996025947A3 (en) | Induction of e-selectin for targetting therapeutic agents | |
| DE69333775D1 (de) | Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten | |
| Plaut et al. | Increase in histamine receptors on thymus-derived effector lymphocytes during the primary immune response to alloantigens | |
| IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
| NZ505834A (en) | Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use | |
| CA2194485A1 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
| HU9601684D0 (en) | Deuterised active agents in transdermal application | |
| ES2183890T3 (es) | Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas. | |
| EP1100515A4 (en) | $ I (EX VIVO) TREATMENT OF ALLOGENIC AND XENOGENIC T CELLS USING gp39 ANTAGONISTS | |
| ATE263833T1 (de) | Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen | |
| EP1152767B1 (de) | Verfahren zur herstellung antitumoraler th1-zellen | |
| FI941451A0 (fi) | Entsymaattisesti valmistettu dimeerinen IL-2 ja sen valmistuksessa käytettävä, hermoista johdettu transglutaminaasi | |
| UA32157A (uk) | Спосіб лікування діабетичної ретинопатії | |
| AR027614A2 (es) | Compuesto de purina l-nucleosido, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| MX9708989A (es) | Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas. | |
| UA36324A (uk) | Спосіб стимуляції гемопоетичної активності кріоконсервованого аломієлотрансплантата |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |